Canaccord reiterates High Tide stock Buy rating on Q3 results

High Tide reported fiscal Q3 2026 revenue of C$199 million, up 33% year over year and 11% sequentially, exceeding the C$137.41 million consensus estimate by 45%. Adjusted EPS of C$0.12 beat estimates by C$0.11, while adjusted EBITDA rose 53% to a record C$16.2 million and net income increased to C$12.7 million from C$0.8 million a year earlier. Canaccord reiterated its Buy rating and C$7.50 target as High Tide plans to open more than 20 Canadian locations in 2026 and expand its German medical-cannabis presence.

Analysis

The earnings beat is less informative than it appears because the largest growth contributor was not fully consolidated in the prior comparison period. The investable question is whether High Tide can convert acquired/distributed revenue into durable retail gross profit and cash generation; the reported opex leverage is encouraging, but cannabis retail remains a low-margin, promotional category where new-store openings can dilute mature-store productivity. The discrepancy between reported adjusted profitability and the trailing per-share loss also makes GAAP-to-adjusted reconciliation, share-based compensation, lease costs, and working-capital conversion essential before underwriting the stated earnings inflection.

Near term, HITI could rerate if it delivers another quarter of positive free cash flow while maintaining EBITDA margin above 8% and demonstrates same-store sales resilience as it adds locations. The key 1-3 month catalyst is a clean outlook showing organic growth separate from acquisition/consolidation effects; analyst price targets have limited signaling value in a thinly traded micro-cap without this disclosure. Over 6-18 months, German medical-market participation and potential U.S. optionality should receive little valuation credit until regulatory access, capital requirements, and a defined operating model are disclosed; both could instead absorb management bandwidth and capital.

Consensus appears to be extrapolating operating leverage without assigning sufficient probability to Canadian price competition and regulatory friction. A higher-rate backdrop is particularly relevant: a business still proving sustainable profitability is more exposed to equity-financing dilution and multiple compression than the headline revenue growth suggests. This is not a read-through for CF; the supplied ticker has no evident economic linkage to the cannabis thesis.

Key Decisions for Investors

• Watch, rather than initiate at the post-results reaction: require two consecutive quarters of positive operating cash flow/free cash flow and adjusted EBITDA margin at or above 8% before taking a long HITI position. This filters for a genuine earnings inflection rather than consolidation-driven growth.
• For a speculative 6-12 month position, use a small long HITI allocation only after management discloses same-store sales, gross-margin trend, net debt/lease-adjusted leverage, and dilution assumptions for the 20+ store plan. Target a rerating on sustained positive GAAP EPS; exit if EBITDA margin falls below 6% or free cash flow reverses materially.
• Do not capitalize German or U.S. expansion optionality in base-case valuation. Add only on independently verifiable regulatory authorization plus evidence that entry can be funded from internal cash flow rather than discounted equity issuance.
• Use HITI as a relative-value long only against a Canadian cannabis retailer with demonstrably weaker cash conversion and higher leverage, if borrow is available; avoid an outright sector-beta trade because regulatory headlines can dominate fundamentals over days to weeks.